
Hong Sang
Examiner (ID: 14344, Phone: (571)272-8145 , Office: P/1643 )
| Most Active Art Unit | 1643 |
| Art Unit(s) | 1646, 1643 |
| Total Applications | 1298 |
| Issued Applications | 583 |
| Pending Applications | 145 |
| Abandoned Applications | 615 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 17275830
[patent_doc_number] => 20210382028
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-12-09
[patent_title] => MEANS AND METHODS FOR DETECTING SOY ALLERGENS
[patent_app_type] => utility
[patent_app_number] => 17/283915
[patent_app_country] => US
[patent_app_date] => 2019-10-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9433
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17283915
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/283915 | MEANS AND METHODS FOR DETECTING SOY ALLERGENS | Oct 10, 2019 | Pending |
Array
(
[id] => 17227196
[patent_doc_number] => 20210353752
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-11-18
[patent_title] => TREATMENT WITH HIGHLY SILYLATED IGG COMPOSITIONS
[patent_app_type] => utility
[patent_app_number] => 17/284188
[patent_app_country] => US
[patent_app_date] => 2019-10-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8780
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -26
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17284188
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/284188 | TREATMENT WITH HIGHLY SILYLATED IGG COMPOSITIONS | Oct 10, 2019 | Abandoned |
Array
(
[id] => 17274458
[patent_doc_number] => 20210380656
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-12-09
[patent_title] => BINDING PROTEINS SPECIFIC FOR HA-1H AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/283786
[patent_app_country] => US
[patent_app_date] => 2019-10-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 42536
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -23
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17283786
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/283786 | Binding proteins specific for HA-1 | Oct 8, 2019 | Issued |
Array
(
[id] => 17563165
[patent_doc_number] => 20220127314
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-04-28
[patent_title] => LEUCINE-RICH ALPHA2 GLYCOPROTEIN COMPOSITION
[patent_app_type] => utility
[patent_app_number] => 17/282325
[patent_app_country] => US
[patent_app_date] => 2019-10-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 3317
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17282325
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/282325 | Leucine-rich ALPHA2 glycoprotein composition | Oct 7, 2019 | Issued |
Array
(
[id] => 15895429
[patent_doc_number] => 20200147233
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-05-14
[patent_title] => METHOD FOR KILLING TUMOR CELLS AND COMPOSITION USED THEREFOR
[patent_app_type] => utility
[patent_app_number] => 16/592143
[patent_app_country] => US
[patent_app_date] => 2019-10-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8153
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -8
[patent_words_short_claim] => 42
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16592143
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/592143 | METHOD FOR KILLING TUMOR CELLS AND COMPOSITION USED THEREFOR | Oct 2, 2019 | Abandoned |
Array
(
[id] => 15681353
[patent_doc_number] => 20200095340
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-03-26
[patent_title] => DLL3 BINDING PROTEINS AND METHODS OF USE
[patent_app_type] => utility
[patent_app_number] => 16/583070
[patent_app_country] => US
[patent_app_date] => 2019-09-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 47093
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -26
[patent_words_short_claim] => 46
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16583070
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/583070 | DLL3 binding proteins and methods of use | Sep 24, 2019 | Issued |
Array
(
[id] => 17385634
[patent_doc_number] => 20220033486
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-02-03
[patent_title] => USE OF ANTAGONISTS OF TH17 CYTOKINES FOR THE TREATMENT OF BRONCHIAL REMODELING IN PATIENTS SUFFERING FROM ALLERGIC ASTHMA
[patent_app_type] => utility
[patent_app_number] => 17/276882
[patent_app_country] => US
[patent_app_date] => 2019-09-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5669
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 29
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17276882
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/276882 | Use of antagonists of Th17 cytokines for the treatment of bronchial remodeling in patients suffering from allergic asthma | Sep 23, 2019 | Issued |
Array
(
[id] => 18356010
[patent_doc_number] => 11644405
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-05-09
[patent_title] => Use of tumor dissociation reagent in flow cytometry
[patent_app_type] => utility
[patent_app_number] => 16/570083
[patent_app_country] => US
[patent_app_date] => 2019-09-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 5
[patent_figures_cnt] => 6
[patent_no_of_words] => 4016
[patent_no_of_claims] => 3
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 126
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16570083
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/570083 | Use of tumor dissociation reagent in flow cytometry | Sep 12, 2019 | Issued |
Array
(
[id] => 17370015
[patent_doc_number] => 20220025067
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-01-27
[patent_title] => HIGHLY EFFICIENT ANTI-TFPI ANTIBODY COMPOSITION
[patent_app_type] => utility
[patent_app_number] => 17/276276
[patent_app_country] => US
[patent_app_date] => 2019-09-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6456
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 37
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17276276
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/276276 | Highly efficient anti-TFPI antibody composition | Sep 5, 2019 | Issued |
Array
(
[id] => 17200186
[patent_doc_number] => 20210340281
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-11-04
[patent_title] => FUSION POLYPEPTIDE COMPRISING POLYPEPTIDE REGION THAT CAN BE O-GLYCOSYLATED
[patent_app_type] => utility
[patent_app_number] => 17/273591
[patent_app_country] => US
[patent_app_date] => 2019-09-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13436
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 54
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17273591
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/273591 | FUSION POLYPEPTIDE COMPRISING POLYPEPTIDE REGION THAT CAN BE O-GLYCOSYLATED | Sep 3, 2019 | Pending |
Array
(
[id] => 17157284
[patent_doc_number] => 20210318335
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-10-14
[patent_title] => BIOMARKERS, COMPOSITIONS, AND METHODS FOR DIAGNOSING AND TREATING SUBJECTS EXPOSED TO PROTEIN/HEPARIN COMPLEXES
[patent_app_type] => utility
[patent_app_number] => 17/271841
[patent_app_country] => US
[patent_app_date] => 2019-08-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13458
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17271841
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/271841 | BIOMARKERS, COMPOSITIONS, AND METHODS FOR DIAGNOSING AND TREATING SUBJECTS EXPOSED TO PROTEIN/HEPARIN COMPLEXES | Aug 27, 2019 | Abandoned |
Array
(
[id] => 19940519
[patent_doc_number] => 12312641
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-05-27
[patent_title] => Sensitivity marker for antibody-drug conjugate
[patent_app_type] => utility
[patent_app_number] => 17/269615
[patent_app_country] => US
[patent_app_date] => 2019-08-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 7
[patent_figures_cnt] => 8
[patent_no_of_words] => 17612
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 154
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17269615
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/269615 | Sensitivity marker for antibody-drug conjugate | Aug 21, 2019 | Issued |
Array
(
[id] => 16013565
[patent_doc_number] => 20200181625
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-06-11
[patent_title] => METHODS AND COMPOSITIONS FOR SECRETION OF HETEROLOGOUS POLYPEPTIDES
[patent_app_type] => utility
[patent_app_number] => 16/548599
[patent_app_country] => US
[patent_app_date] => 2019-08-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 42193
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -27
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16548599
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/548599 | Methods and compositions for secretion of heterologous polypeptides | Aug 21, 2019 | Issued |
Array
(
[id] => 18012125
[patent_doc_number] => 11504399
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-11-22
[patent_title] => Combination therapy for a stable and long term engraftment using specific protocols for T/B cell depletion
[patent_app_type] => utility
[patent_app_number] => 16/538954
[patent_app_country] => US
[patent_app_date] => 2019-08-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 7
[patent_figures_cnt] => 11
[patent_no_of_words] => 23968
[patent_no_of_claims] => 24
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 310
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16538954
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/538954 | Combination therapy for a stable and long term engraftment using specific protocols for T/B cell depletion | Aug 12, 2019 | Issued |
Array
(
[id] => 15254199
[patent_doc_number] => 20190375833
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-12-12
[patent_title] => USE OF TGF-ALPHA POLYPEPTIDE OR ANTI-TGF-ALPHA ANTIBODIES FOR THE TREATMENT OF DISEASES AND DISORDERS
[patent_app_type] => utility
[patent_app_number] => 16/534691
[patent_app_country] => US
[patent_app_date] => 2019-08-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18019
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -64
[patent_words_short_claim] => 18
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16534691
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/534691 | USE OF TGF-ALPHA POLYPEPTIDE OR ANTI-TGF-ALPHA ANTIBODIES FOR THE TREATMENT OF DISEASES AND DISORDERS | Aug 6, 2019 | Abandoned |
Array
(
[id] => 16087021
[patent_doc_number] => 20200197497
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-06-25
[patent_title] => PEPTIDIC CHIMERIC ANTIGEN RECEPTOR T CELL SWITCHES AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 16/532860
[patent_app_country] => US
[patent_app_date] => 2019-08-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 30445
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16532860
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/532860 | PEPTIDIC CHIMERIC ANTIGEN RECEPTOR T CELL SWITCHES AND USES THEREOF | Aug 5, 2019 | Abandoned |
Array
(
[id] => 15681337
[patent_doc_number] => 20200095332
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-03-26
[patent_title] => Antigen-Binding Fusion Proteins with Modified HSP70 Domains
[patent_app_type] => utility
[patent_app_number] => 16/532200
[patent_app_country] => US
[patent_app_date] => 2019-08-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 25750
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16532200
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/532200 | Antigen-binding fusion proteins with modified HSP70 domains | Aug 4, 2019 | Issued |
Array
(
[id] => 17996690
[patent_doc_number] => 11497776
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-11-15
[patent_title] => Combination therapy for a stable and long term engraftment
[patent_app_type] => utility
[patent_app_number] => 16/508325
[patent_app_country] => US
[patent_app_date] => 2019-07-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 7
[patent_figures_cnt] => 11
[patent_no_of_words] => 15912
[patent_no_of_claims] => 22
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 170
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16508325
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/508325 | Combination therapy for a stable and long term engraftment | Jul 10, 2019 | Issued |
Array
(
[id] => 15254165
[patent_doc_number] => 20190375816
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-12-12
[patent_title] => HIGH AVIDITY ANTIGEN RECOGNIZING CONSTRUCTS
[patent_app_type] => utility
[patent_app_number] => 16/507803
[patent_app_country] => US
[patent_app_date] => 2019-07-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7932
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 30
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16507803
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/507803 | High avidity antigen recognizing constructs | Jul 9, 2019 | Issued |
Array
(
[id] => 17126256
[patent_doc_number] => 20210301024
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-09-30
[patent_title] => COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY TARGETING FLT3, PD-1, AND/OR PD-L1
[patent_app_type] => utility
[patent_app_number] => 17/257553
[patent_app_country] => US
[patent_app_date] => 2019-07-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 43845
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17257553
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/257553 | COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY TARGETING FLT3, PD-1, AND/OR PD-L1 | Jul 2, 2019 | Abandoned |